We conducted a systematic review, a meta-analysis, and a dose-response meta-analysis of all randomized clinical trials (RCTs) investigating the effects of intranasal oxytocin as an add-on to antipsychotic treatment on the negative symptoms of schizophrenia. Here, OXT is linked to schizophrenia.